📰 Nasdaq Edit News
Page 5 - Nasdaq Edit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.
June 1, 2023
UBS Group AG lifted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 357.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 407,014 shares of the company’s stock after buying an additional 318,113 shares during the quarter. UBS Group AG’s holdings in Editas Medicine were worth $3,610,000 at the end […]
May 17, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 18,860,000 shares, a decline of 5.5% from the April 15th total of 19,950,000 shares. Based on an average trading volume of 1,770,000 shares, the […]
May 16, 2023
StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Friday morning. EDIT has been the topic of several other research reports. Morgan Stanley decreased their price target on shares of Editas Medicine from $8.00 to $7.00 and set […]
May 16, 2023
Michelle Robertson to remain with Company until August 16, 2023...
May 13, 2023
Editas Medicine (NASDAQ:EDIT – Get Rating) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Friday. A number of other brokerages also recently issued reports on EDIT. SVB Leerink lifted their price target on Editas Medicine from $6.00 to $7.00 and gave the stock a […]
May 6, 2023
Editas Medicine (NASDAQ:EDIT – Get Rating) released its earnings results on Friday. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.08, Briefing.com reports. The firm had revenue of $9.90 million for the quarter, compared to analyst estimates of $3.29 million. Editas Medicine had a negative […]
April 19, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The […]
April 17, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) shares shot up 8.4% during trading on Monday . The stock traded as high as $8.32 and last traded at $8.23. 443,238 shares were traded during trading, a decline of 75% from the average session volume of 1,793,685 shares. The stock had previously closed at $7.59. Wall Street […]
March 25, 2023
Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) have been given an average rating of “Hold” by the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to […]
March 24, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) fell 4.3% during trading on Wednesday . The company traded as low as $7.70 and last traded at $7.70. 317,125 shares traded hands during trading, a decline of 82% from the average session volume of 1,730,446 shares. The stock had previously closed at $8.05. Analyst Upgrades and Downgrades […]